RxDoctor Payments DataLook up a doctor →

Ike Onwere, MD

Hematology & Oncology · Corvallis, ORNPI 1467454025

Payments from drug & device makers

$71,666in general payments, 2019–2025

Across 277 payments — averaging $258.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$48K
  • Bristol Myers Squibb$8K
  • Novartis$7K
  • Genentech USA, Inc.$2K
  • Boehringer Ingelheim$1K
  • Janssen Scientific Affairs, LLC$1K
  • plus $4K from 43 others

What the payments were for

  • Consulting fees$10,39060%
  • Travel & lodging$1,5169%
  • Food & beverage$4,59527%
  • Education$6824%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,666 in reported general payments places this provider in the 60th percentile of 112 hematology & oncology providers in Oregon.

See all hematology & oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$130,056
Medicare patients
214
Services billed
1,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$386,747
KisqaliRibociclib Succinate13$225,954
InlytaAxitinib11$214,102
CalquenceAcalabrutinib Maleate15$204,990
RevlimidLenalidomide12$201,314
JakafiRuxolitinib Phosphate12$169,081
EliquisApixaban141$90,802
XareltoRivaroxaban26$19,825
Abiraterone Acetate14$2,606
Ondansetron Hcl91$1,952
Anastrozole79$1,471
Exemestane17$1,458
Acyclovir76$1,274
Enoxaparin Sodium28$1,067
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav55$1,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$89$386,74727 claims
PfizerInlyta, Eliquis$171$304,904152 claims
NovartisKisqali$7,204$225,95413 claims
AstraZenecaCalquence$340$204,99015 claims
Bristol Myers SquibbRevlimid$7,556$201,31412 claims
Incyte CorporationJakafi$47,613$169,08112 claims
Johnson & JohnsonXarelto$481$19,82526 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$1,024$2,60614 claims
Lilly USA, LLCOlanzapine$337$97623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 112 hematology & oncology providers in Oregon.

Other hematology & oncology in Corvallis

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →